Creative Medical Technology Holdings received FDA clearance for expanded dosing in Phase 1/2 trial of StemSpine® for chronic back pain

From GlobeNewswire: 2025-03-20 07:50:00

Creative Medical Technology Holdings, Inc. received FDA clearance for expanded dosing in its Phase 1/2 trial of StemSpine® for chronic lower back pain. Interim data shows significant pain reduction and improved mobility. The study, using CELZ-201-DDT, has a 4:1 treatment ratio with no serious adverse events reported. The FDA approval allows for enhanced treatment optimization. CEO Timothy Warbington is optimistic about the therapy’s potential as a non-opioid solution. CELZ-201-DDT is a regenerative therapy targeting degenerative disc disease. The company remains committed to innovative regenerative medicine solutions for pain management and tissue regeneration.



Read more at GlobeNewswire: Creative Medical Technology Holdings Secures FDA Clearance